H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 33.6 DKK 1.97%
Market Cap: 33.5B DKK
Have any thoughts about
H Lundbeck A/S?
Write Note

H Lundbeck A/S
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

H Lundbeck A/S
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
H Lundbeck A/S
CSE:HLUN A
Net Change in Cash
kr1.5B
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Novo Nordisk A/S
CSE:NOVO B
Net Change in Cash
kr27.1B
CAGR 3-Years
89%
CAGR 5-Years
59%
CAGR 10-Years
24%
ALK-Abello A/S
CSE:ALK B
Net Change in Cash
kr253m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Net Change in Cash
kr5.1m
CAGR 3-Years
3%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
No Stocks Found

H Lundbeck A/S
Glance View

Market Cap
33.3B DKK
Industry
Pharmaceuticals

Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.

HLUN A Intrinsic Value
65.73 DKK
Undervaluation 49%
Intrinsic Value
Price

See Also

What is H Lundbeck A/S's Net Change in Cash?
Net Change in Cash
1.5B DKK

Based on the financial report for Dec 31, 2023, H Lundbeck A/S's Net Change in Cash amounts to 1.5B DKK.

What is H Lundbeck A/S's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
17%

Over the last year, the Net Change in Cash growth was 15%. The average annual Net Change in Cash growth rates for H Lundbeck A/S have been 17% over the past three years .

Back to Top